Pentadeca Arginate Reconstitution Calculator
Pentadeca Arginate, sold as PDA, is marketed as an arginate salt of BPC-157 that is claimed to be more stable and better absorbed than the acetate form. No part of that claim has been published: a PubMed search across every name variant returns zero abstracts, no registered trial and no FDA label names it, and there is no structural characterisation or analytical method for the molecule in the literature. It is supplied as a lyophilised powder or a pre-mixed vial, so the mixing volume sets the concentration. This calculator converts a vial size and a mixing volume into mg/ml and syringe units. It does not tell you what to inject, and no dose for this compound has ever been studied.
No established human dose
Pentadeca Arginate has essentially no published literature. Nobody has established a dose for it, and this page does not state one.
The calculator below converts a vial size and a mixing volume into a concentration. That is arithmetic about the vial, not a recommendation about what to inject.
What the evidence says
Pentadeca Arginate has no scientific literature at all. A PubMed search across every name variant for this compound — 'Pentadeca Arginate', 'pentadeca arginate', 'pentadecapeptide arginate' and 'BPC-157 arginate' — returned zero abstracts, and no registered clinical trial and no FDA label names it. That is not a thin evidence base; it is an empty one.
This entry is `not_studied` rather than `no_human_dosing_data` for a specific reason: `no_human_dosing_data` means the compound has been studied in animals or in vitro but never dosed in people. PDA has not been studied in anything. There is no rodent work, no cell work, no structural characterisation and no analytical chemistry to summarise, so evidence_level is left unset — there is no evidence to assign a level to.
Every dose figure clinics publish for PDA is carried over from BPC-157 practice, which is itself uncited: BPC-157 has no human dosing trial either. So the advertised 250-500 mcg daily is a borrowed number from a compound whose own numbers are unsupported. The one thing a user should take from this entry is that nobody — not the vendors, not this library — knows what an appropriate dose is, whether the molecule in the vial is what the label claims, or what it does over weeks of daily injection.
Pentadeca Arginate at a glance
- Category
- Healing peptide
- Half-life
- Not established
- Routes
- Subcutaneous, Intramuscular
- Regulatory status
- Research use only
- Also sold as
- PDA, pentadecapeptide arginate, BPC-157 arginate, Pentadecapeptide Arginate
Mechanism
No mechanism has been published for this molecule. Vendors describe Pentadeca Arginate as an arginate salt of BPC-157, claimed to be more stable and better absorbed than the acetate form, and they carry across BPC-157's proposed angiogenic and tissue-repair mechanism wholesale. That description has never appeared in a peer-reviewed publication: there is no structural characterisation, no stability comparison, no receptor or pathway work, and no demonstration that the arginate form behaves in the body like BPC-157 at all. The mechanism attributed to PDA is therefore a marketing claim about a related compound, not a finding about this one — and BPC-157's own mechanism is itself established only in rodents and cell culture.
Reconstitution
Powder vials are reconstituted with bacteriostatic water; some operators supply a pre-mixed solution (e.g. 10 mg/mL). Because no analytical method or reference standard for this molecule exists in the published literature, there is no way for a buyer or a pharmacist to confirm that a vial contains what the label says, at the concentration the label says.
Storage
Supplied as a lyophilised powder or a pre-mixed multi-dose vial. There is no approved product, no published stability data and no independent analysis of any commercial preparation, so no storage or shelf-life claim about this compound can be verified. The stability advantage that is the entire selling point of the arginate form has never been measured in public.
Frequency in practice
No established regimen exists and none has ever been studied. Clinics that sell it list a daily subcutaneous injection, or 2-3 sessions per week, in cycles of 4-12 weeks — figures carried over from BPC-157 practice.
Regulatory
Not approved by any regulator, anywhere, for any indication, and not a compounded version of an approved drug — it has no approved reference product. It is sold directly by wellness and rejuvenation clinics and by peptide vendors, often positioned as a legally safer successor to BPC-157 after FDA restrictions on that compound. Nothing in the published record supports treating it as a distinct, characterised substance.
What to know before anything else
There is no published science on Pentadeca Arginate. No clinical trial, no animal study, no pharmacology, no pharmacokinetics, no toxicology and no safety report of any kind exists for this molecule.
It is sold on the claim that it is a more stable arginate salt of BPC-157. That claim has never been published or independently verified — and even if it were true, BPC-157 has no established human dose either, so every advertised PDA dose rests on two unverified links: that PDA behaves like BPC-157, and that BPC-157's own uncited practice figures are right.
Because nothing is published, there is no basis for any statement about interactions, contraindications, use in pregnancy, long-term use, or what happens above the advertised dose. Absence of reported harm here reflects absence of anyone looking, not evidence of safety.
Product identity is unverifiable. With no published analytical method and no reference standard in the literature, neither a buyer nor a compounding pharmacist can confirm a vial labelled PDA contains the claimed molecule at the claimed strength.
Advertised doses vary between operators by more than twofold (200-500 mcg) and the schedules disagree (daily versus 2-3 times weekly), which is what a market with no underlying data looks like.
Being newer than BPC-157 is not a safety advantage — it means less is known, not that less can go wrong.
Pentadeca Arginate questions
Is there an established dose for Pentadeca Arginate?
No. A PubMed search across all four name variants for this compound — 'Pentadeca Arginate', 'pentadeca arginate', 'pentadecapeptide arginate' and 'BPC-157 arginate' — returns zero abstracts, no registered clinical trial names it, and no FDA label names it. That is not a thin evidence base; it is an empty one. Every dose figure clinics publish for PDA is carried over from BPC-157 practice, which is itself uncited: BPC-157 has no human dosing trial either.
What is actually known about how Pentadeca Arginate works?
Nothing has been published about its mechanism. Vendors describe PDA as an arginate salt of BPC-157 and carry BPC-157's proposed angiogenic and tissue-repair mechanism across wholesale, but that description has never appeared in a peer-reviewed publication. There is no stability comparison between the arginate and acetate forms, no receptor or pathway work, and no demonstration that the arginate form behaves in the body like BPC-157 at all. The mechanism attributed to PDA is a marketing claim about a related compound, and BPC-157's own mechanism is established only in rodents and cell culture.
What do clinics selling Pentadeca Arginate actually list?
Wellness and rejuvenation clinics that sell PDA commonly list 250-500 mcg subcutaneously, most often once daily, with some listing 2-3 sessions per week and some starting as low as 200 mcg. That is purely what clinics advertise. It is not established by any human trial, and every listed figure is borrowed from BPC-157 practice rather than derived from PDA data. Advertised amounts vary between operators by more than twofold and the schedules disagree with each other, which is what a market with no underlying data looks like.
Can a buyer verify that a PDA vial contains what the label says?
No. There is no published analytical method and no reference standard for this molecule in the literature, so neither a buyer nor a compounding pharmacist can confirm that a vial labelled PDA contains the claimed molecule at the claimed strength. The same gap defeats every storage and shelf-life claim: there is no approved product and no published stability data, and the stability advantage that is the entire selling point of the arginate form has never been measured in public.
How does reconstitution volume change the numbers on a PDA vial?
The vial holds a fixed mass of peptide and the bacteriostatic water sets the concentration. A 10 mg vial mixed with 2 ml gives 5 mg/ml, so 0.1 ml on the barrel is 500 mcg; the same vial mixed with 5 ml gives 2 mg/ml and that same 0.1 ml is 200 mcg. Some operators skip this step entirely and supply a pre-mixed solution at a stated 10 mg/mL, which is a concentration nobody outside the seller has verified. Enter your own vial size and mixing volume above rather than copying a unit count from a clinic page.
How is Pentadeca Arginate regulated?
It is not approved by any regulator, anywhere, for any indication, and it is not a compounded version of an approved drug because it has no approved reference product. It is sold directly by wellness and rejuvenation clinics and by peptide vendors, often positioned as a legally safer successor to BPC-157 after FDA restrictions on that compound. Nothing in the published record supports treating it as a distinct, characterised substance.
Is PDA safer than BPC-157 because it is newer?
Being newer means less is known, not that less can go wrong. There is no pharmacology, no pharmacokinetics, no toxicology and no safety report of any kind for this molecule, so there is no basis for any statement about interactions, contraindications, use in pregnancy, long-term use, or what happens above the advertised amount. Absence of reported harm here reflects the absence of anyone looking. Any advertised PDA dose also rests on two unverified links: that PDA behaves like BPC-157, and that BPC-157's own uncited practice figures are right.
The rest of the math
- Reconstitution calculatorThe full version of the tool above, with syringe barrel sizes and IU conversion.
- Vial longevityHow many doses a vial holds and the date it runs out.
- Cost per doseVial price against doses drawn, so two vial sizes can be compared honestly.
- Half-life and decayFirst-order clearance, time to steady state, and what remains at a given hour.
Same class as Pentadeca Arginate
You worked out the draw. Now log this dose.
A calculator answers once and forgets. Dosavy keeps the concentration you mixed, the doses you actually took, and a reminder for the next one — with the same evidence labels you see on this page.